Peter Olagunju
Chief Operating Officer at TCR2 THERAPEUTICS INC.
Peter Olagunju active positions
Companies | Position | Start | End |
---|---|---|---|
TCR2 THERAPEUTICS INC. | Chief Operating Officer | 31/12/2022 | - |
Chief Tech/Sci/R&D Officer | 20/07/2021 | 31/12/2022 |
Career history of Peter Olagunju
Former positions of Peter Olagunju
Companies | Position | Start | End |
---|---|---|---|
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/03/2020 | 01/07/2021 |
BLUEBIRD BIO, INC. | Corporate Officer/Principal | 01/02/2015 | 01/03/2020 |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Corporate Officer/Principal | - | - |
DENDREON CORPORATION | Corporate Officer/Principal | - | - |
Training of Peter Olagunju
University of Washington | Masters Business Admin |
University of Illinois At Urbana–Champaign | Undergraduate Degree |
Statistics
International
United States | 8 |
Operational
Corporate Officer/Principal | 4 |
Chief Operating Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectoral
Health Technology | 6 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
Private companies | 4 |
---|---|
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
Dendreon Corp.
Dendreon Corp. Medical SpecialtiesHealth Technology Dendreon Corp. discovers, develops and commercializes novel products for the treatment of cancer. The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types. It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. Dendreon was founded by Christopher S. Henney, Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA. | Health Technology |
ZymoGenetics, Inc.
ZymoGenetics, Inc. Pharmaceuticals: MajorHealth Technology ZymoGenetics, Inc. develops protein based drugs. It focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases, including homeostasis, inflammatory and autoimmune diseases, cancer, and viral infections. The company was founded by Earl W. Davie, Benjamin D. Hall and Michael Smith in 1981 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Peter Olagunju
- Experience